Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

Moderna (MRNA) PT Lowered to $185 at Morgan Stanley Following EPS

February 23, 2023 12:39 PM EST

Morgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA) to $185.00 (from $205.00) while maintaining a Overweight rating following earnings.

The analyst commented, "4Q22 was generally in-line. 2023 COGS of 35-40% was above expectations and the most notable downside driver in our... More

Moderna (MRNA) Q4 Revenue Tops Consensus

February 23, 2023 7:05 AM EST

Moderna (NASDAQ: MRNA) reported Q4 EPS of $3.61, $1.09 worse than the analyst estimate of $4.70. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.05 billion.

2023 Financial Framework

Advance Purchase Agreements (APAs): The Company has COVID vaccine sales of approximately $5 billion currently contracted for... More